Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polymorphisms in the p53 pathway.

E C Pietsch1, O Humbey, M E Murphy

  • 1Division of Medical Sciences, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Oncogene
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temocillin use as a carbapenem-sparing option in a UK teaching hospital for treating serious Gram-negative bacterial infections.

JAC-antimicrobial resistance·2022
Same author

A Cross-Sectional Study of Antibiotic Prescribing for Childhood Upper Respiratory Tract Infections in Irish General Practice

Irish medical journal·2018
Same author

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study.

BMC medicine·2018
Same author

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

BMC medicine·2018
Same author

Real-world use of fidaxomicin in a large UK tertiary hospital: how effective is it for treating recurrent disease?

The Journal of hospital infection·2018
Same author

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies.

Blood cancer journal·2017
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
Same journal

Correction: SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Oncogene·2026
Same journal

Correction: Liver-specific SIRT1 knockout-induced hyperglycemia promotes spontaneous lung adenocarcinomas through HSF1-MDM2.

Oncogene·2026
Same journal

Correction: 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.

Oncogene·2026
See all related articles

Polymorphisms in the p53 tumor suppressor gene and its target genes can impair function, influencing cancer risk and therapy efficacy. Understanding these genetic variations is crucial for personalized cancer treatment strategies.

Area of Science:

  • Oncology
  • Cancer Genetics
  • Molecular Biology

Background:

  • The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in up to 50% of tumors.
  • p53's role in inducing growth arrest or apoptosis is critical for preventing cancer development.
  • Polymorphisms in p53 and its target genes that impair function are surprisingly common.

Purpose of the Study:

  • To review the nature of polymorphic variants in the p53 pathway.
  • To elucidate the mechanisms by which these polymorphisms impair p53 pathway function.
  • To discuss the impact of these polymorphisms on cancer risk and therapeutic outcomes.

Main Methods:

  • Review of existing literature on p53 gene and pathway polymorphisms.
  • Analysis of mechanisms by which polymorphisms affect protein function.

Related Experiment Videos

  • Discussion of implications for cancer risk and therapy.

    • Main Results:

    • Identified polymorphic variants in p53 and its target genes that compromise their tumor-suppressive functions.
    • Elucidated mechanisms of functional impairment by these polymorphisms.
    • Highlighted the emerging understanding of how these variations impact cancer risk and treatment.

    Conclusions:

    • Polymorphisms in the p53 pathway represent a significant factor in cancer development and progression.
    • Future research should focus on mouse models and haplotype analyses of p53 variants for better insights.
    • Understanding inter-individual genotypic differences is key to advancing personalized cancer therapy and prognosis.